Stewart Robert L, Chan Kwan L
Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Curr Cardiol Rev. 2009 Jan;5(1):29-35. doi: 10.2174/157340309787048103.
Patients with symptomatic severe aortic stenosis (AS) benefit from aortic valve replacement surgery, but the management of patients with asymptomatic severe AS is more controversial. While cholesterol and angiotensin have been linked to AS progression, we should await the results of ongoing randomized trials before medical therapy to lower cholesterol or inhibit angiotensin can be recommended to limit disease progression. Clinical factors, echocardiographic parameters, valve morphology, exercise stress testing results, and cardiac biomarkers may be useful in identifying patients who will have early development of symptoms during follow-up and require closer monitoring. The risks associated with aortic valve replacement outweigh the benefits in the majority of patients with asymptomatic severe AS.
有症状的重度主动脉瓣狭窄(AS)患者可从主动脉瓣置换手术中获益,但无症状重度AS患者的管理更具争议性。虽然胆固醇和血管紧张素与AS进展有关,但在推荐降低胆固醇或抑制血管紧张素的药物治疗以限制疾病进展之前,我们应等待正在进行的随机试验结果。临床因素、超声心动图参数、瓣膜形态、运动负荷试验结果和心脏生物标志物可能有助于识别在随访期间将早期出现症状并需要密切监测的患者。在大多数无症状重度AS患者中,主动脉瓣置换相关风险大于获益。